Tvardi Therapeutics, Inc. (TVRD) Discusses Phase 1 Data on TTI-109 STAT3 Inhibitor Highlighting Prodrug Design, Tolerability and Target Engagement Transcript
· seekingalpha.com
Tvardi Therapeutics, Inc. (TVRD) Discusses Phase 1 Data on TTI-109 STAT3 Inhibitor Highlighting Prodrug Design, Tolerability and Target Engagement July 7,...
Presentation
I will now turn the call over to P.J. Kelleher of LifeSci Advisors. Please go ahead, P.J.
Good morning, and welcome to the Tvardi Therapeutics In...